ENTRY       D10410                      Drug
NAME        Vantictumab (USAN/INN)
FORMULA     C6322H9722N1674O1988S46
EXACT_MASS  142371.8264
MOL_WEIGHT  142459.8511
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFS HYTLSWVRQA PGKGLEWVSV ISGDGSYTYY
            ADSVKGRFTI SSDNSKNTLY LQMNSLRAED TAVYYCARNF IKYVFANWGQ GTLVTVSSAS
            TKGPSVFPLA PCSRSTSEST AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
            YSLSSVVTVP SSNFGTQTYT CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF
            PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV
            SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE KTISKTKGQP REPQVYTLPP SREEMTKNQV
            SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS FFLYSKLTVD KSRWQQGNVF
            SCSVMHEALH NHYTQKSLSL SPG
            (Light chain)
            DIELTQPPSV SVAPGQTARI SCSGDNIGSF YVHWYQQKPG QAPVLVIYDK SNRPSGIPER
            FSGSNSGNTA TLTISGTQAE DEADYYCQSY ANTLSLVFGG GTKLTVLGQP KAAPSVTLFP
            PSSEELQANK ATLVCLISDF YPGAVTVAWK ADSSPVKAGV ETTTPSKQSN NKYAASSYLS
            LTPEQWKSHR SYSCQVTHEG STVEKTVAPT ECS
            (Disulfide bridge: H22-H96, L22-L87, H'22-H'96, L'22-L'87, H132-L212, H'132-L'212, L135-L194, L'135-L'194, H145-H201, H'145-H'201, H220-H'220, H221-H'221, H224-H'224, H227-H'227, H258-H318, H'258-H'318, H364-H422, H'364-H'422; Glycosylation site: Asn-H294, Asn-H'294)
  TYPE      Peptide
EFFICACY    Antineoplastic, Anti-Frizzled family receptor 7 antibody
  TYPE      Monoclonal antibody
TARGET      FZD7 [HSA:8324] [KO:K02432]
  PATHWAY   hsa04310(8324)  Wnt signaling pathway
            hsa05200(8324)  Pathways in cancer
BRITE       Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Frizzled / Smoothened family
               Frizzled
                FZD7
                 D10410  Vantictumab (USAN/INN)
DBLINKS     CAS: 1345009-45-1
            PubChem: 172232503
///
